Iovance Biotherapeutics, Inc. Common Stock

IOVA Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
IOVA Income Statement
IOVA Balance Sheet
IOVA Cash Flow
Congress Trading

Recent trades of IOVA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
IOVA Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
IOVA Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
IOVA Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by IOVA's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $260,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $260,000 Oct 11, 2022 Issue: Medicare/Medicaid Health Issues
  • $260,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $50,000 Apr 20, 2022 Issue: Medicare/Medicaid
  • $50,000 Apr 19, 2022 Issue: Health Issues
  • $50,000 Jan 20, 2022 Issue: Health Issues
  • $50,000 Jan 19, 2022 Issue: Medicare/Medicaid
  • $50,000 Oct 20, 2021 Issue: Medicare/Medicaid
  • $50,000 Oct 20, 2021 Issue: Health Issues
  • $50,000 Jul 20, 2021 Issue: Medicare/Medicaid
  • $50,000 Jul 19, 2021 Issue: Health Issues
  • $40,000 Apr 20, 2021 Issue: Medicare/Medicaid
  • $40,000 Apr 19, 2021 Issue: Health Issues
  • $30,000 Jan 21, 2021 Issue: Medicare/Medicaid
  • $30,000 Jan 19, 2021 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Dec. 03, 2024
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Oct. 22, 2024
  • Patent Title: Processes for generating til products enriched for tumor antigen-specific t-cells Oct. 01, 2024
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 09, 2024
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 02, 2024
  • Patent Title: Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof Jul. 02, 2024
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jun. 04, 2024
  • Patent Title: Til expansion processes using specific cytokine combinations and/or akti treatment May. 14, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 07, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 30, 2024
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 26, 2024
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 09, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 09, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 02, 2024
  • Patent Title: Methods of using tumor infiltrating lymphocytes in double-refractory melanoma Nov. 21, 2023
  • Patent Title: Processes for generating til products enriched for tumor antigen-specific t-cells Aug. 01, 2023
  • Patent Title: Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion Jun. 06, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 16, 2023
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Apr. 18, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 03, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 20, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 06, 2022
  • Patent Title: Methods of using tumor infiltrating lymphocytes in double-refractory melanoma Sep. 06, 2022
  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Aug. 02, 2022
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 12, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 28, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 21, 2022
  • Patent Title: Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof Jun. 14, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 07, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 07, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 31, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 31, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 31, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 24, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 26, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 19, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 19, 2022
  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Apr. 05, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 05, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 15, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 15, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Mar. 08, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 22, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 08, 2022
  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Jan. 11, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 21, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 21, 2021
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Nov. 23, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Nov. 09, 2021
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Nov. 09, 2021
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of IOVA in WallStreetBets Daily Discussion

IOVA News

Recent insights relating to IOVA

CNBC Recommendations

Recent picks made for IOVA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in IOVA

IOVA Top Shareholders
Shareholder
Shares Held
IOVA Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

IOVA Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view IOVA Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top